The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic

Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. (Source: Bloomberg)

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.